Relapsing-remitting


Also found in: Acronyms.

Relapsing-remitting

A pattern of symptoms of multiple sclerosis in which symptomatic attacks occur that last 24 hours or more, followed by complete or almost complete improvement.
Mentioned in: Multiple Sclerosis
References in periodicals archive ?
Right now, 900 volunteers with relapsing-remitting MS are in a two-year international, double-blind, placebo-controlled study, which should provide definitive data on how well it Works.
DNA therapeutics company Synthetic Biologics Inc (NYSE Amex:SYN) revealed on Wednesday the completion of the enrollment in a Phase II clinical trial evaluating the efficacy and safety of estriol Trimesta for the treatment of relapsing-remitting multiple sclerosis (MS).
The INCOMIN trial studied 188 people with relapsing-remitting MS--92 participants were randomly assigned to take Avonex (interferon beta-1a) once a week; 96 were randomly assigned to take Betaseron (interferon beta-1b) every other day.
In the European Union (EU), Gilenya is approved for people with highly active relapsing-remitting MS despite treatment with beta interferon, or in patients with rapidly evolving severe relapsing-remitting MS.
Fred Lublin (New York, NY) and his colleagues extended an earlier study in which 33 people with relapsing-remitting MS using Avonex (interferon beta-1a) were also given Copaxone (glatiramer acetate).
TYSABRI is approved in USA for relapsing forms of MS and in the European Union for relapsing-remitting MS.
Forty-five patients with relapsing-remitting MS began Betaseron treatment at the London (Ont.
1 December 2009 - German Bayer Schering Pharma AG (OTC: SHRGY) said today that the Chinese State Food and Drug Administration (SFDA) has approved Betaferon (interferon beta-1b) therapy for patients with relapsing-remitting multiple sclerosis (MS).
In 1986, Toni Vidal was diagnosed with relapsing-remitting MS.
MCT-125 targets the chronic fatigue symptom in MS patients, while MCT-175 is being developed as a treatment of relapsing-remitting MS.
A study published in the August 28, 2001 issue of Neurology showed that Copaxone (glatiramer acetate for injection) reduced the number of permanent "black holes" that developed in people with relapsing-remitting MS.
of Petah Tikva, Israel, announced results from an interim analysis of the CORAL trial, an international, multi-center clinical trial of oral Copaxone (glatiramer acetate) in over 1,600 men and women with relapsing-remitting MS.